Leerink Partners Adjusts Price Target on Bristol-Myers Squibb to $60 From $54, Maintains Outperform Rating

Leerink Partners Adjusts Price Target on Bristol-Myers Squibb to $60 From $54, Maintains Outperform Rating — alphai